Sei Investments CO Bei Gene, Ltd. Transaction History

Sei Investments CO

$69 Billion
Q2 2024

A detailed history of Sei Investments CO transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Sei Investments CO holds 24,248 shares of BGNE stock, worth $5.97 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

24,248

Previous 23,400 3.62%

Holding current value

$5.97 Million

Previous $3.66 Million 5.47%

% of portfolio

0.01%

Previous 0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$129.52 - $174.32 $109,832 - $147,823	848 Added 3.62%	24,248 $3.46 Million
Q1 2024 May 07, 2024	SELL	$141.8 - $181.47 $5.1 Million - $6.53 Million	-35,994 Reduced 60.6%	23,400 $3.66 Million
Q4 2023 Feb 14, 2024	SELL	$158.67 - $201.58 $706,081 - $897,031	-4,450 Reduced 6.97%	59,394 $10.7 Million
Q3 2023 Nov 14, 2023	SELL	$179.87 - $225.13 $1.42 Million - $1.78 Million	-7,892 Reduced 11.0%	63,844 $11.5 Million
Q2 2023 Aug 11, 2023	BUY	$178.3 - $266.78 $521,884 - $780,865	2,927 Added 4.25%	71,736 $12.8 Million
Q1 2023 May 12, 2023	BUY	$215.53 - $274.5 $11.7 Million - $14.9 Million	54,373 Added 376.65%	68,809 $14.8 Million
Q4 2022 Feb 10, 2023	BUY	$125.51 - $229.3 $263,571 - $481,530	2,100 Added 17.02%	14,436 $3.18 Million
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $79,080 - $121,344	600 Added 5.11%	12,336 $1.66 Million
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $744,826 - $1.33 Million	6,150 Added 110.1%	11,736 $1.9 Million
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $102,406 - $160,408	-412 Reduced 6.87%	5,586 $1.51 Million
Q3 2021 Nov 12, 2021	SELL	$249.6 - $403.14 $111,072 - $179,397	-445 Reduced 6.91%	5,998 $2.18 Million
Q2 2021 Aug 06, 2021	SELL	$292.75 - $367.01 $48,011 - $60,189	-164 Reduced 2.48%	6,443 $2.21 Million
Q1 2021 May 12, 2021	SELL	$260.64 - $382.12 $1.98 Million - $2.9 Million	-7,594 Reduced 53.48%	6,607 $2.3 Million
Q4 2020 Feb 08, 2021	SELL	$221.31 - $316.61 $534,242 - $764,296	-2,414 Reduced 14.53%	14,201 $3.67 Million
Q3 2020 Dec 04, 2020	SELL	$189.18 - $286.44 $3,216 - $4,869	-17 Reduced 0.1%	16,615 $4.76 Million
Q3 2020 Nov 06, 2020	BUY	$189.18 - $286.44 $1.17 Million - $1.78 Million	6,198 Added 59.4%	16,632 $4.76 Million
Q2 2020 Aug 17, 2020	BUY	$123.9 - $195.41 $77,313 - $121,935	624 Added 6.36%	10,434 $1.97 Million
Q2 2020 Aug 11, 2020	SELL	$123.9 - $195.41 $83,756 - $132,097	-676 Reduced 6.45%	9,810 $1.63 Million
Q1 2020 May 14, 2020	BUY	$121.84 - $173.19 $82,973 - $117,942	681 Added 6.95%	10,486 $1.29 Million
Q4 2019 Feb 06, 2020	SELL	$115.78 - $208.34 $26,745 - $48,126	-231 Reduced 2.3%	9,805 $1.63 Million
Q3 2019 Nov 12, 2019	BUY	$120.61 - $148.29 $168,974 - $207,754	1,401 Added 16.22%	10,036 $1.23 Million
Q2 2019 Aug 14, 2019	BUY	$113.99 - $146.86 $967,775 - $1.25 Million	8,490 Added 5855.17%	8,635 $1.07 Million
Q1 2019 May 15, 2019	BUY	$122.82 - $151.83 $17,808 - $22,015	145 New	145 $19,000
Q1 2018 May 11, 2018	SELL	$97.41 - $177.22 $2,143 - $3,898	-22 Closed	0 $0
Q3 2017 Nov 06, 2017	BUY	$66.19 - $103.46 $1,456 - $2,276	22	22 $2,000

Others Institutions Holding BGNE

# of Institutions

213

Shares Held

45.1M

Call Options Held

106K

Put Options Held

93.1K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $25.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.

Account

Sei Investments CO Bei Gene, Ltd. Transaction History